Roberts Agrylin
Executive Summary
Indication for anagrelide expanded Dec. 16 to treatment of patients with "thrombocythemia, secondary to myeloproliferative disorders," to reduce the elevated platelet count and the risk of thrombosis and to "ameliorate associated symptoms including thrombo-hemorrhagic events." The drug was previously indicated for essential thrombocythemia